Calocurb CLINICAL Maintenance Pack

Description:

Calocurb^® CLINICAL is a practitioner-exclusive supplement that supports appetite control by working with the body’s natural hormonal signals. It features Amarasate^®, a clinically studied extract of New Zealand bitter hops, delivered in a delayed-release capsule designed to reach the small intestine where it activates bitter taste receptors. This triggers the release of key satiety hormones including GLP-1, CCK and PYY, which work together to significantly reduce hunger, cravings, and caloric intake. Fast-acting and plant-based, Calocurb^® CLINICAL offers a targeted, science-driven approach to supporting healthy weight management.

Clinical Applications

• Reduces Appetite and Food Cravings
• Supports Long-Term Weight Management
• Stimulates Natural GLP-1, CCK and PYY Release
• Complements Lifestyle and Pharmaceutical Weight Loss Strategies
• Enhances Adherence to Intermittent Fasting and Time-Restricted Eating

Benefits

In 2019, the first clinical study on Amarasate^® was conducted in a randomized, double-blind trial investigating its appetite suppressive effects during a 24-hour, water-only fast. Participants given Amarasate^® or placebo at hours 16 and 20 were evaluated for hunger and satiety with a standard visual analog scale (VAS) every 30 minutes after capsule administration. Amarasate^® participants reported an 80% reduction in hunger elevation scores compared to the placebo group. In a comparable water-fast study conducted in women, Amarasate^® supplementation led to a 100% suppression of hunger elevation and a 120% reduction in food cravings relative to placebo.

A more expansive study of adult men sought to correlate the subjective reduction in hunger from the first study with anorexigenic biomarkers, specifically GLP-1, CCK and PYY. The study also sought to investigate which was more efficacious, intragastric or intraduodenal delivery of Amarasate^®. In the randomized, double-blind study, the subjects were given either placebo, intraduodenal Amarasate^® (delayed-release capsule), or intragastric Amarasate^® (immediate-release capsule) one hour before an ad libitum meal and subsequent snack. Both Amarasate^® delivery methods had significant elevations in GLP-1, CCK and PYY; however, the intragastric capsule also had significantly more adverse events than the intraduodenal capsule likely due to the high amount of TAS2R bitter receptors in the stomach. Intraduodenal delivery of Amarasate^® resulted in 600% elevation from baseline of GLP-1 and CCK, and 50% elevation of PYY.

Directions for Use:

Contains: 60 x 250 mg capsules
Patients should continue on a dose of Calocurb® CLINICAL 250 mg twice daily, using the Maintenance Pack.
Take one 250 mg capsule, twice daily, one hour before a meal.
Always take on an empty stomach with a minimum of 8 ounces of water.

DOES NOT CONTAIN
Sugar, starch, yeast, wheat, gluten, soy, milk, eggs, shellfish, fish, peanuts, tree nuts. No artificial colors, flavors or preservatives.

*Claims are from the manufacturer and not Victress Health or wholesaler*